Giuseppe
Emeritus
[Source: Eurosurveillance, full text: (LINK). Extract, edited.]
Eurosurveillance, Volume 16, Issue 39, 29 September 2011
Meeting reports
Highlights from the clinical symposium on Shiga toxin-producing Escherichia coli / haemolytic uremic syndrome, Berlin, September 2011
A Jansen (
)<SUP>1</SUP>
Citation style for this article: Jansen A. Highlights from the clinical symposium on Shiga toxin-producing Escherichia coli / haemolytic uremic syndrome, Berlin, September 2011. Euro Surveill. 2011;16(39)
ii=19977. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19977
Date of submission: 23 September 2011 <HR>
On 9 September 2011, the Estrel Convention Center in Berlin was the venue for a first clinical symposium on Shiga toxin-producing Escherichia coli / haemolytic uremic syndrome (STEC/HUS) reflecting on the large STEC outbreak in Germany earlier this year. The German Society of Nephrology (DGfN) invited internationally renowned clinical experts and microbiologists to discuss the basic science and diagnostics of STEC infections and the different options for treating an EHEC-associated HUS, including plasmapheresis, antibody therapy with Eculizumab, and extracorporeal immune adsorption.
Opening the symposium, Helge Karch from M?nster University Clinic gave a brief update on the microbiology and the diagnosis of STEC strains. He pointed out that a STEC O104:H4 strain was first isolated in Germany in 2001 from a child with HUS [1]. This strain (HUSEC041) was not identical with the 2011 outbreak strain, but showed similar molecular features (like the outbreak strain, this isolate was (stx2)-positive and (eae)-negative). A specific multiplex PCR for the 2011 outbreak strain has been developed within three days after the first isolate was available, and was made publicly accessible [2]. Interestingly, the microbiological features of the outbreak strain as known by today could not explain its pathogenicity as observed in the outbreak, leaving several open questions.
(?)
- -------
Eurosurveillance, Volume 16, Issue 39, 29 September 2011
Meeting reports
Highlights from the clinical symposium on Shiga toxin-producing Escherichia coli / haemolytic uremic syndrome, Berlin, September 2011
A Jansen (
- European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
Citation style for this article: Jansen A. Highlights from the clinical symposium on Shiga toxin-producing Escherichia coli / haemolytic uremic syndrome, Berlin, September 2011. Euro Surveill. 2011;16(39)
ii=19977. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19977 Date of submission: 23 September 2011 <HR>
On 9 September 2011, the Estrel Convention Center in Berlin was the venue for a first clinical symposium on Shiga toxin-producing Escherichia coli / haemolytic uremic syndrome (STEC/HUS) reflecting on the large STEC outbreak in Germany earlier this year. The German Society of Nephrology (DGfN) invited internationally renowned clinical experts and microbiologists to discuss the basic science and diagnostics of STEC infections and the different options for treating an EHEC-associated HUS, including plasmapheresis, antibody therapy with Eculizumab, and extracorporeal immune adsorption.
Opening the symposium, Helge Karch from M?nster University Clinic gave a brief update on the microbiology and the diagnosis of STEC strains. He pointed out that a STEC O104:H4 strain was first isolated in Germany in 2001 from a child with HUS [1]. This strain (HUSEC041) was not identical with the 2011 outbreak strain, but showed similar molecular features (like the outbreak strain, this isolate was (stx2)-positive and (eae)-negative). A specific multiplex PCR for the 2011 outbreak strain has been developed within three days after the first isolate was available, and was made publicly accessible [2]. Interestingly, the microbiological features of the outbreak strain as known by today could not explain its pathogenicity as observed in the outbreak, leaving several open questions.
(?)